Kynurenine

Kynurenine

SCHEMBL288988

Nc1ccccc1C(=O)CC(N)C(=O)O.Nc1ccccc1C(=O)CC(N)C(=O)O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.64
HIF1A Q16665 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
KYNU Q16719 2/20 0.49
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
ALPI P09923 1/20 0.47
PKM P14618 1/20 0.47
PTGS1 P23219 1/20 0.47
XIAP P98170 1/20 0.47
SLC7A5 Q01650 1/20 0.47
KMO O15229 3/20 0.45
SLC1A3 P43003 2/20 0.45
SLC1A2 P43004 2/20 0.45
SLC1A1 P43005 2/20 0.45
GRM2 Q14416 1/20 0.45
GRM3 Q14832 1/20 0.45
GRIK1 P39086 1/20 0.43
ALDH1A1 P00352 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Kynurenine SCHEMBL288254 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
Kynurenine SCHEMBL29349989 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
L-Kynurenine SCHEMBL29396313 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
L-Kynurenine SCHEMBL29415716 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
L-Kynurenine SCHEMBL288989 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
L-Kynurenine SCHEMBL13969610 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
L-Kynurenine SCHEMBL20875 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
Kynurenine SCHEMBL20874 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
Kynurenine SCHEMBL2181581 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
Kynurenine SCHEMBL2368792 0.98 KDM4E (0.62) KDM4EHIF1ATDP1KYNUGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024058984-A2 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MarvelBiome, Inc. (US) 2024-03-21 WO disclosed
US-20230086254-A1 MEDICINAL COMPOSITION COMPRISING DENTAL PULP-DERIVED CELLS JCR PHARMACEUTICALS CO., LTD. (JP) 2023-03-23 US disclosed
WO-2018134329-A1 METABOLIC BIOMARKER SET FOR ASSESSING OVARIAN CANCER BIOCRATES LIFE SCIENCES AG (AT) 2018-07-26 WO disclosed
EP-3191845-A1 BIOMARKERS FOR ASSESSING BREAST CANCER IDCGS Clínica de Diagnósticos Médicos Ltda (BR) 2017-07-19 EP disclosed
EP-3126841-A1 BIOMARKERS FOR ASSESSING HIV IDCGS clinica de Diagnosticos Medicos (BR) 2017-02-08 EP disclosed
WO-2016038157-A1 BIOMARKERS FOR ASSESSING BREAST CANCER IDCGS CLÍNICA DE DIAGNÓSTICOS MÉDICOS LTDA (BR) 2016-03-17 WO disclosed
WO-2015150360-A1 BIOMARKERS FOR ASSESSING HIV IDCGS CLINICA DE DIAGNOSTICOS MEDICOS (BR) 2015-10-08 WO disclosed
CN-104487457-A Target tissue specific antigen binding molecules CHUGAI PHARMACEUTICAL CO LTD 2015-04-01 CN disclosed
WO-2012113834-A1 METHOD AND USE OF METABOLITES FOR THE DIAGNOSIS OF INFLAMMATORY BRAIN INJURY IN PRETERM BORN INFANTS BIOCRATES LIFE SCIENCES AG (AT) 2012-08-30 WO disclosed
EP-2427773-A1 METHOD OF DIAGNOSING ASPHYXIA Keller, Matthias (DE) 2012-03-14 EP disclosed
WO-2011062628-A1 METHODS AND COMPOSITIONS FOR MODULATION OF T CELLS VIA THE KYNURENINE PATHWAY NEW YORK UNIVERSITY (US) 2011-05-26 WO disclosed
WO-2010128054-A1 METHOD OF DIAGNOSING ASPHYXIA BIOCRATES LIFE SCIENCES AG (AT) 2010-11-11 WO disclosed